A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment by Gonçalves, Anthony et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
A polymorphism of EGFR extracellular domain is associated with 
progression free-survival in metastatic colorectal cancer patients 
receiving cetuximab-based treatment
Anthony Gonçalves*†1,2,6,7, Séverine Esteyries†3,6,7, Brynn Taylor-Smedra2,6,7, 
Arnaud Lagarde3,7, Mounay Ayadi1, Geneviève Monges4,6,7, 
François Bertucci1,3,6,7, Benjamin Esterni1,7, Jean-Robert Delpero5,6,7, 
Olivier Turrini5, Bernard Lelong5, Patrice Viens1,6,7, Jean-Paul Borg2,6,7, 
Daniel Birnbaum3,6,7, Sylviane Olschwang3,7 and Frédéric Viret1,7
Address: 1Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France, 2Department of Molecular Pharmacology, Institut Paoli-
Calmettes, Marseille, France, 3Department of Molecular Oncology, Institut Paoli-Calmettes, Marseille, France, 4Department of BioPathology, 
Institut Paoli-Calmettes, Marseille, France, 5Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France, 6Université de la 
Méditerranée, UFR de Médecine, Marseille, France and 7INSERM U891 ; Centre de Recherche en Cancérologie de Marseille, Marseille, France
Email: Anthony Gonçalves* - goncalves.anthony2@orange.fr; Séverine Esteyries - esteyries@marseille.inserm.fr; Brynn Taylor-
Smedra - brynntaylor@hotmail.com; Arnaud Lagarde - lagarde@marseille.inserm.fr; Mounay Ayadi - oncomed@marseille.fnclcc.fr; 
Geneviève Monges - mongesg@marseille.fnclcc.fr; François Bertucci - bertuccif@marseille.fnclcc.fr; 
Benjamin Esterni - esternib@marseille.fnclcc.fr; Jean-Robert Delpero - delperojr@marseille.fnclcc.fr; 
Olivier Turrini - turrinio@marseille.fnclcc.fr; Bernard Lelong - lelongb@marseille.fnclcc.fr; Patrice Viens - viensp@marseille.fnclcc.fr; Jean-
Paul Borg - borg@marseille.inserm.fr; Daniel Birnbaum - birnbaum@marseille.inserm.fr; Sylviane Olschwang - olschwangs@marseille.fnclcc.fr; 
Frédéric Viret - viretf@marseille.fnclcc.fr
* Corresponding author    †Equal contributors
Abstract
Background: Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor
(EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for
therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are
potential determinants of cetuximab activity.
Methods: We analyzed tumor tissues from 32 EGFR-positive mCRC patients receiving cetuximab/
irinotecan combination and evaluable for treatment response. EGFR copy number was quantified
by fluorescence in situ hybridization (FISH). KRAS exon 1 and EGFR exons coding for extracellular
regions were sequenced.
Results:  Nine patients experienced an objective response (partial response) and 23 were
considered as nonresponders (12 with stable disease and 11 with progressive disease). There was
no EGFR amplification found, but high polysomy was noted in 2 patients, both of which were
cetuximab responders. No EGFR mutations were found but a variant of exon 13 (R521K) was
observed in 12 patients, 11 of which achieved objective response or stable disease. Progression-
free and overall survivals were significantly better in patients with this EGFR exon 13 variant. KRAS
mutations were found in 14 cases. While there was a trend for an increased KRAS mutation
frequency in nonresponder patients (12 mutations out of 23, 52%) as compared to responder
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patients (2 out of 9, 22%), authentic tumor response or long-term disease stabilization was found
in KRAS mutated patients.
Conclusion: This preliminary study suggests that: an increase in EGFR copy number may be
associated with cetuximab response but is a rare event in CRC, KRAS mutations are associated with
low response rate but do not preclude any cetuximab-based combination efficacy and EGFR exon
13 variant (R521K) may predict for cetuximab benefit.
Background
Epidermal growth factor receptor (EGFR), which partici-
pates in signaling pathways that are deregulated in cancer
cells, is a promising target in epithelial cancer, notably
colorectal cancer [1]. Cetuximab (Erbitux®), a monoclonal
antibody targeting EGFR, is currently used in EGFR-
expressing metastatic colorectal cancer (mCRC) in combi-
nation with cytotoxic chemotherapy (irinotecan), after
failure of a previous irinotecan-based regimen. In this set-
ting, cetuximab produces objective response in about
25% of patients, with nearly 30% of patients achieving
disease stabilization [2], resulting in a median progres-
sion-free survival of 4 months and a median overall sur-
vival of 6 to 9 months. Recently, another EGFR-targeted
monoclonal antibody, panitumumab (vectibix®) was
FDA-approved in mCRC as single agent, after failing
chemotherapy drugs fluoropyrimidine, oxaliplatin and
irinotecan[3]. Panitumumab induces a response rate of
10%, similar to that achieved with single-agent cetuximab
in a similar patient population [4,5], and demonstrates a
modest but significant increase in median progression-
free survival against best supportive care.
Clearly, clinical benefit with EGFR-targeting antibodies
seems to be restricted to a particular subgroup of mCRC
patients. However, no validated predictive factor is cur-
rently available to improve the rational administration of
these therapies in this patient population. Such factors are
critically needed, especially if we consider the high cost of
these new therapeutics[6] and their expected future inte-
gration in regimens administered in earlier clinical stages,
including first-line treatment of mCRC and adjuvant
chemotherapy in stage III localized disease.
Somatic mutations of EGFR tyrosine kinase domain are
associated with exquisite sensitivity to EGFR-tyrosine
kinase inhibitors erlotinib and gefitinib in non-small cell
lung cancer (NSCLC) [7-9], but such mutations are rare or
absent in CRC [5,10]. EGFR protein expression, as evalu-
ated by immunohistochemistry, does not correlate with
response [2,4,11] and only specific treatment-induced
skin rash seems associated with tumor response and pro-
gression-free survival [2].
Recent retrospective data have suggested that EGFR ampli-
fication or KRAS exon 1 somatic mutations may allow a
better selection of patients who are candidates for EGFR
targeting [12,13]. In a first study [12], an increase in EGFR
copy number identified by FISH (fluorescence in situ
hybridization) was found in all but one responding
patients, while four recent studies identified no or few
cetuximab responders in KRAS mutated patients [13-17].
In the present retrospective study of 32 patients with
EGFR-positive mCRC treated with cetuximab-based com-
bination, we have analyzed EGFR copy number by FISH
and sequenced the extracellular domains (ECD) of EGFR,
as well as KRAS exon 1, and correlated these data with
clinical outcome.
Methods
Patients and treatment
We retrospectively assessed 32 patients with EGFR-posi-
tive mCRC treated with cetuximab-irinotecan combina-
tion at the Institut PAOLI-CALMETTES, Marseille, France
between March 2004 and July 2005 who were evaluable
for tumor response and had available pre-treatment fro-
zen and/or formalin-fixed and paraffin-embedded tumor
tissues (from primary and/or metastatic tumor tissue).
EGFR positivity was defined by at least 1% malignant cells
demonstrating EGFR immunostaining (antibody from
Zymed Laboratories, Inc., San Francisco, 1/20, digested
with pepsin). In 26 patients, cetuximab was used accord-
ing to official registration in irinotecan-resistant patients
and administered as a loading dose of 400 mg/m2 intra-
venously, followed by 250 mg/m2 once a week until pro-
gression, in combination with irinotecan 180 mg/m2
every other week. In addition, 6 patients received cetuxi-
mab/irinotecan in specific clinical trials evaluating:
- a dose escalation of cetuximab in irinotecan-resistant
patients (n = 3)
- cetuximab in combination with Folfiri as first-line treat-
ment (n = 2) or as second-line treatment after failure of
first-line fluoropyrimidine/oxaliplatin (n = 1).
Tumor evaluation was performed with appropriate meth-
ods within four weeks of treatment initiation and
repeated during treatment every 2 months for the first 6
months and then every 3 months until disease progres-
sion. WHO criteria of response were used [18]. Briefly, theBMC Cancer 2008, 8:169 http://www.biomedcentral.com/1471-2407/8/169
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sum of products of target lesions was calculated and
response was determined as follows: complete response
(CR), disappearance of all target lesions without any
residual lesion; partial response (PR), 50% or more
decrease in target lesions; progressive disease (PD), 25%
or more increase in the size of measurable lesions or
appearance of new lesions; stable disease (SD), neither PR
or PD criteria are met. This study was approved by an
institutional review board and patient consent for analysis
of stored biological samples, in relation with clinical data
including imagery data, was verified for all patients
included.
EGFR copy number by FISH
Formalin-fixed paraffin-embedded (FFPE) tissue sections
(5 μm) were placed in pretreatment solution for 60 min at
80°C, and digested with pepsin solution for 15 min at
37°C. Dual-color, dual-target FISH assays were done with
the SPEC EGFR/CEN7 Dual Color Probe Kit (ZytoVision,
Bremerhaven, Germany). Tissue sections, covered with
10-μL probe solution, were incubated at 75°C for 10 min
to co-denature EGFR and CEN7 (chromosome seven α-
centromeric) probes and allowed to hybridize overnight
at 37°C. Codenaturation and hybridization were done
sequentially in a microprocessor-controlled system
(Hybridizer, DakoCytomation, Glostrup, Denmark).
Posthybridization stringency wash was done in a water
bath at 37°C for 5 min. After washing 4 times and drying
at room temperature for 15 min, tissue sections were cov-
ered with 4'-6-diamidino-2-phenylindole (DAPI/Antifade
Solution, ZytoVision, Bremerhaven, Germany) for chro-
matin counterstaining before microscopy. Sample mate-
rial was evaluated by fluorescence microscopy (Leica. DM
RXA). Filter sets for the following wavelength ranges were
required: EGFR (ZyGreen), excitation at 503 nm and
emission at 528 nm, similar to FITC; chromosome 7
(ZyOrange), excitation at 547 nm and emission at 572
nm, similar to Rhodamine.
Two independent observers (SE and AL) scored at least
100 non-overlapping interphase nuclei for the number of
copies of EGFR and CEN7 by use of predefined scoring
guidelines. The negative controls consisted of a healthy
colorectal mucosa adjacent to malignant disease; the con-
trol for amplified EGFR was an amplified colonic adeno-
carcinoma. FISH patterns were defined as described in
[19] : Briefly, the samples were grouped as follows: nor-
mal disomy, two gene copies in more than 90% of cells;
trisomy, three gene copies in more than 10% of cells and
ratio gene/chromosomes ≤ 2 ; low polysomy, at least four
gene copies in more than 10% but fewer than 40% of cells
and ratio gene/chromosomes ≤ 2; high polysomy, at least
four gene copies in more than 40% cells and ratio gene/
chromosomes ≤ 2; and gene amplification, ratio gene/
chromosome more than two or 15 gene copies in at least
10% of cells. Trisomy and low polysomy were not consid-
ered as increases in EGFR copy number. Tumors showing
high polysomy and/or gene amplification were consid-
ered to be FISH positive and as significant increases in
EGFR copy number.
DNA extraction and mutation analyses
DNA was extracted from frozen (n = 20) or FFPE colorec-
tal cancer samples (n = 12) with the QIAamp DNA mini-
kit (Qiagen). For FFPE tissues, samples were obtained by
pinching tissue fragments within a tumor zone under
microscopic control. Exon 1 of KRAS, the site of the most
frequent activating mutations in codons 12 and 13, and
exons 6 to 14 of EGFR, corresponding to the transmem-
brane and extracellular domains, were sequenced after
PCR amplification of each exon using the BigDye termina-
tor kit v1.1 (Applied Biosystems) and the PhredPhrap-
Consed package. Genotypes were assessed with the
GeneMapper software (Applied Biosystems).
Statistical analyses
Fischer's exact test was used to calculate p-values for the
association between genetic parameters and response to
cetuximab. Progression-free survival (PFS) was calculated
from the date of cetuximab initiation to the date of disease
progression, date of death if it occurred before progres-
sion, or date of last news. Overall survival (OS) was calcu-
lated from the date of cetuximab initiation to the date of
death or the date of last news. Survivals were estimated
with the Kaplan-Meier method. Survival curves were com-
pared using the log-rank test. Analysis was carried out
using the R software. The level of significance was set at p
= 0.05.
Results
Patient population
Patient characteristics are summarized in table 1. Cetuxi-
mab was administered after failing 2 or more regimens in
22 patients. Twenty-four patients had been previously
exposed to fluoropyrimidines, irinotecan and oxaliplatin.
Median follow-up was 19.1 months. An objective
response was observed in 9 patients (RR = 28%; CI95%,
15–45%), and 12 patients experienced stable disease,
which lasted 6 months or more for 2 patients. Eleven
patients progressed at the first evaluation. Median pro-
gression-free and overall survivals were 4.1 months
(CI95%, 3.6–6.3) and 17.2 months (CI95%, 13.8-NR),
respectively.
EGFR copy numer analysis
No authentic regional amplification was observed. An
increased EGFR copy number was noted in 12 patients
(Table 2), but was considered as significant in only 2
patients, corresponding to high polysomy (patients 1 and
3, Figure 1). Both patients responded to cetuximab.BMC Cancer 2008, 8:169 http://www.biomedcentral.com/1471-2407/8/169
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EGFR sequencing
We sequenced EGFR exons 6 to 14 coding for the trans-
membrane and extracellular domains. No mutation was
found, but a heterozygous (9 patients) or homozygous (3
patients) point substitution G→A on exon 13, resulting in
the amino acid substitution of arginine by lysine in posi-
tion 521 (R521K), was detected in 12 patients. This vari-
ant was observed in 11 of 21 patients achieving objective
response (4 patients) or stable disease (7 patients) and in
1 of 11 patients with rapidly progressive disease (defined
as progression at time of the first evaluation) (p = 0.02,
Fischer's exact test) (Table 2). As shown in figure 2A,
median PFS and OS were significantly better in patients
with the R521K variant than in wild-type patients (5.7
[CI95%, 4.3-NR] vs. 3.2 [CI95%, 2.5–4.7] months; p =
0.041, log-rank test for PFS; 20.1 [CI95%, 16-NR] vs. 13.8
[CI95%, 7.7-NR] months; p = 0.03 log-rank for OS).
KRAS mutations
Sequencing of KRAS exon 1 was performed and correlated
with clinical outcome (Table 2). Fourteen patients dis-
played KRAS exon 1 mutations (codon 12 for 10 patients,
codon 13 for 4 patients). Of the 32 genotyped tumors, 19
were metastases and 13 were primary tumors. In six
patients, paired primary and metastatic tumors were avail-
able; no discordance was observed between the geno-
types. In 9 responding patients, 2 had a KRAS mutation
(22%), whereas 12 of 23 (52%) nonresponding patients
had a KRAS mutation. This difference was not statistically
significant (p = 0.234, Fischer's exact test). As shown in
figure 2B, PFS was similar in KRAS-nonmutated and
KRAS-mutated patients: median PFS was 3.9 months (CI
95%, 2.5–11) and 4.7 months (CI 95%, 2.7–11.3) (p =
0.968, log-rank test) in KRAS-nonmutated and KRAS-
mutated patients, respectively. Overall survival was better
in KRAS-nonmutated (20.8 months [CI 95%, 14.5-NR])
than in KRAS-mutated patients (13.8 months [CI 95%,
11.5-NR]), however this difference did not reach statisti-
cal significance (p = 0.472, log-rank test).
Clinical features of KRAS-mutated benefiting from 
cetuximab based-treatment
To better examine the clinical relevance of response or
long-lasting stable disease obtained by cetuximab-irinote-
can combination in 3 patients with KRAS-mutated
tumors, their medical records were reviewed. The first
patient (Pt 6) was a 53-year-old woman presenting liver
metastases from a primary pT2N2 colon cancer resected in
May 2003. She had received adjuvant LV-5FU (infusional
5FU/folinic acid) chemotherapy between May 2002 and
October 2003. A first hepatic relapse occurred in January
2004 and was treated with two courses of Folfox (5FU,
folinic acid, oxaliplatin) followed by Folfiri (5FU, folinic
acid, irinotecan) due to allergic reaction after oxaliplatin
infusion. The patient achieved a partial response and a
right hepatectomy for metastasis removal was performed
on April 2004, followed by six cycles of Folfiri in August
2004. She had a second hepatic relapse in September
2004 and in October 2004 was subjected to radiofre-
quency ablation which failed, resulting in the appearance
of an additional hepatic lesion. The patient started cetux-
imab in association with irinotecan in January 2005 and
achieved an authentic partial response allowing surgical
removal in April 2005 (Figure 3A). Surgery was patholog-
ically complete and the patient was alive in complete
remission at time of last news in May 2006.
The second responding patient with a KRAS mutation (Pt
7) was a 52-year-old woman who had been treated in June
1999 for a primary adenocarcinoma of the rectum classi-
fied pT4N2. The patient received post-operative radio-
chemotherapy with Fufol (Bolus 5FU/folinic acid) on
week 1 and 5. In February 2000, she had liver metastases
that were completely surgically removed. In December
2000, she had a second hepatic relapse and received an
association of 5FU/irinotecan/oxaliplatin for 2 months
allowing her to be a candidate for a second complete sur-
gical removal which was performed in April 2001. On Jan-
uary 2003, she experienced a third relapse involving
retroperitoneal lymph nodes which was treated with Folf-
iri until May 2003, when a partial response was achieved.
Maintenance with capecitabine was initiated and contin-
Table 1: Patient population
Patients
Characteristics number percentage
All patients 16
Sex
Male 16 50%
Female 16 50%
Age, years
Median 58
Range 36–78
Tumor site
Colon 21 65%
Rectum 11 35%
Previous adjuvant chemotherapy
Yes 10 31%
No 22 69%
Line of cetuximab use
Median 3
Range 1–5
Response status
CR 0
PR 9 28.1%
SD 12 37.5%
PD 11 34.4%
CR = Complete response, PR = Partial response, SD = Stable disease 
and PD = Progressive disease were defined as described in the 
methods section.BMC Cancer 2008, 8:169 http://www.biomedcentral.com/1471-2407/8/169
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Table 2: Molecular Alterations in tumors of metastatic colorectal cancer patients
Pt number Sex Age Previous 
adjuvant CT
Type of 
adjuvant CT
Previous 
regimen for 
metastatic 
disease
Tumor Best 
response
Time to 
progression 
(weeks)
KRAS exon 1 EGFR 
exon13
EGFR copy 
Number 
(FISH)
Responders
1 F 70 0 - PR 10 Wild-type R521K high 
polysomy
2 M 62 0 Folfirinox PR 94* Wild-type trisomy
3 F 56 0 Folfiri, Folfox PR 9 Wild-type high 
polysomy
4 M 37 0 Folfiri, 
Folfox, xelox
PR 44 Wild-type low 
polysomy
5 F 44 0 Folfiri, Folfiri PR 33 Wild-type R521K disomy
6 F 54 1 LV5FU Folfiri PR 67 Gly13Asp disomy
7 F 52 1 Fufol Folfirinox, 
Folfiri, 
LV5FU-
mitomycine
PR 42 Gly12Asp R521K disomy
8 M 56 0 Foflfox PR 25 Wild-type disomy
9 M 66 1 Fufol Folfiri, Folfox PR 24* Wild-type R521K trisomy
Non-responders
10 F 68 0 Folfiri, 
Xeloda, 
Xelox
SD 17 Wild-type R521K trisomy
11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy
12 M 61 0 Folfirinox SD 18 Gly13Asp R521K disomy
13 F 71 0 Xelox 
Avastin-
Xeliri
SD 15 Gly12Asp disomy
14 M 59 0 LV5FU, 
Folfiri, Folfox
SD 24 Gly12Cys R521K trisomy
15 M 71 0 Folfox, 
Irinotecan
SD 14 Wild-type disomy
16 F 60 1 Fufol Folfiri, 
Folfox, Cape, 
LV5FU
SD 17 Wild-type trisomy
17 M 65 0 Folfirinox, 
Folfiri
SD 18 Wild-type low 
polysomy
18 M 66 0 Folfiri SD 17 Wild-type R521K disomy
19 F 45 0 Folfox, 
Xelox
SD 17 Wild-type R521K NE
20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy
21 M 62 1 Folfox Xeliri SD 36 Gly13Asp R521K disomy
22 M 58 1 Folfiri Xelox, Xeliri PD NA Gly13Asp disomy
23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy
24 M 81 0 Xelox, Folfiri PD NA Gly12Val disomy
25 F 55 0 Xelox 
Avastin-
Xeliri
PD NA Gly12Asp disomy
26 M 60 1 LV5FU Folfiri, Folfiri, 
Folfox
PD NA Wild-type NE
27 M 59 0 Folfiri, Folfiri/
Folfox, 
Folfox
PD NA Gly12Asp NE
28 F 58 1 LV5FU Folfiri, Xelox PD NA Gly12Asp disomy
29 M 51 0 Folfox, Folfiri PD NA Wild-type disomy
30 F 66 0 Folfiri, Xelox PD NA Wild-type R521K trisomy
31 F 56 0 - PD NA Wild-type disomy
32 F 78 0 Folfox, 
Folfiri, Cape
PD NA Gly12Val disomy
F = female, M = Male, Folfox = oxaliplatin, fluorouracil, and folinic acid; Xelox = capecitabine, oxaliplatin; Folfiri = irinotecan, fluorouracil, and folinic 
acid; Xeliri = Capecitabine, irinotecan; Folfirinox = oxaliplatin, irinotecan, fluorouracil, and folinic acid; LV5FU = infusional FU and folinic acid; Fufol 
= bolus fluorouracil and folinic acid; PR = partial response. SD = stable disease. PD = progressive disease. R521K = point substitution G→A on 
exon 13 EGFR resulting in the amino acid substitution Arg to Lys in position 521. NA = not applicable. NE = not evaluable.BMC Cancer 2008, 8:169 http://www.biomedcentral.com/1471-2407/8/169
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ued until October 2003 when disease progressed on both
lymph nodes and the liver. A palliative treatment was
started combining 5FU and mitomycin C with no
response. The patient started cetuximab with irinotecan in
March 2004, when the compound became available in
France. She experienced a partial response until January
2005 (Figure 3B), when she developed bone metastases
with spinal compression. She died in February 2005.
Finally, a third patient (pt 21) with a KRAS  mutation
achieved long-lasting stable disease (8 months), under
cetuximab-irinotecan treatment. This 62-year old man
had been treated in 2004 for a pT3N2 colon cancer by sur-
gery followed by adjuvant Folfox. In December 2004,
while he was receiving Folfox, he developed liver metas-
tases which were surgically removed. Post-operative treat-
ment was initiated in March 2005 with an association of
capecitabine/irinotecan, but lung metastases occurred
under treatment. A combination of cetuximab and iri-
notecan was started in June 2005 and continued with sta-
ble disease until February 2006 when peritoneal and lung
progression occurred. The patient died in August 2006.
Discussion
In this retrospective and preliminary study including 32
mCRC patients receiving cetuximab-based treatment, we
have analyzed molecular factors that have been suggested
to regulate activity of EGFR-targeted approaches.
EGFR copy number
Using a FISH-based assay, we evaluated EGFR  copy
number and did not observe any EGFR  amplification
(ratio EGFR to Control probes >2 or ≥ 15 gene copies in ≥
10% of cells), although trisomy or polysomy was
observed in 12 patients. Only 2 patients displayed an
increase in EGFR copy number that reached the definition
of high polysomy (≥ four gene copies in ≥ 40% cells).
However, these 2 patients were objective responders to
cetuximab. In previous studies, an increase in EGFR gene
copy number has been observed in 0.6 to 31% of CRC.
These variations may be due in part to the techniques used
to evaluate amplification, which include FISH, CISH or
real-time quantitative PCR. Moreover, amplifications lim-
ited to the EGFR  locus must be distinguished from
extracopies of the entire chromosome 7 which contains
the  EGFR  gene (polysomy). In a study involving 31
Dual color FISH assays for probes of EGFR (green) and chromosome seven (CEP7, red) Figure 1
Dual color FISH assays for probes of EGFR (green) and chromosome seven (CEP7, red). (A) Balanced disomy in 
healthy colorectal mucosa. (B) Balanced disomy in tumor of patient 15. (C) Balanced low polysomy in tumor of patient 4. (D) 
High polysomy in tumor of patient 1. (E) Amplification in a control tumor.
A BC
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patients[12], Moroni et al observed an increase in EGFR
copy number in 8 of the 9 cetuximab-responders but only
in 1 of the 20 nonresponder patients who were assessable
by FISH, suggesting that this increase may represent a
strong positive predictive factor for response to this com-
pound. Of note, an authentic amplification was found in
7 of these 9 patients with increased EGFR copy number.
However, the same group recently reported no actual
EGFR amplification but only polysomy in 58 FISH-ana-
lyzed tumors from mCRC patients receiving panitumu-
mab. These authors have concluded that the previously
observed amplification frequency could have been overes-
timated by scoring as amplified some tumors with only
very limited foci of amplification. Nevertheless, this study
still suggested a significant association between EGFR
copy number and response and survival [20]. Other
groups have reported a lower rate of copy gain, corre-
sponding most often to polysomy [13,21-23]. In one of
these studies which is consistent with our own results,
only 3 patients out of 30 displayed an increase in EGFR
copies as evaluated by CISH [13]; these 3 patients
responded to cetuximab. Thus, a significant increase in
EGFR copy number may be associated with a high proba-
bility of response, even though this molecular alteration
may be relatively rare in mCRC. Furthermore, regarding
the significant number of responding patients without
any significant increase in EGFR copy number in both
Lievre et al's study (8 out of 11 responders) and ours (7
out of 9 responders), we do not believe that this parame-
ter should be considered as a prerequisite for cetuximab
activity.
Survivals according to EGFR and KRAS genotypes Figure 2
Survivals according to EGFR and KRAS genotypes. A/ Progression-free survival (PFS) (Left) and overall survival (OS) 
(Right) curves of patients with EGFR R521K variant and wild-type. B/ PFS (Left) and OS (Right) curves of patients with a KRAS-
mutated and nonmutated tumor.
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KRAS mutations
Recent retrospective data from several independent stud-
ies have shown a very negative association between KRAS
exon 1 mutations and cetuximab response in mCRC
patients. A first group found no KRAS  mutations in
tumors from 11 cetuximab-responding patients, whereas
13 of the 19 nonresponders (p = 0.0003) had a KRAS-
mutated tumor, leading the authors to suggest that KRAS
mutational status could serve to exclude cetuximab use in
mCRC[13]. A second recently published study involving
59 refractory mCRC patients receiving cetuximab-based
treatment confirmed these data by reporting no mutations
in all 12 responding patients, with a significantly worse
time-to-progression in patients with a KRAS  muta-
tion[14]. Additionally, a third report has shown that
mutations affecting either KRAS or BRAF are predictive
and prognostic indicators in mCRC patients, and are
inversely correlated with response to anti-EGFR mono-
clonal antibodies [16]. Another study evaluating KRAS/
BRAF mutation status in 80 patients receiving cetuximab
as single-agent found only 3 KRAS mutated tumors out of
27 patients who experienced a clinical benefit, but 27 out
of 53 nonresponding patients [15]. Finally, recent data
from 27 mCRC patients observed only one responder out
of 10 mutated tumors compared to 9 out of 17 non
mutated tumors[17]. We found a similar trend in our
study, although our observations did not reach statistical
significance. Moreover, pooling all published studies eval-
uating this putative association further suggests that KRAS
mutations strongly negatively affect the probability of
objective response to cetuximab treatment. In these stud-
ies, the response rate in KRAS mutated tumors was 9 out
of 115 (7.8%, CI95%: 3.6–14.3%) versus 81 out of 192
(42.2%, CI95%: 35.1–49.5%) in wild type tumors (p =
3.5 10-10, chi-2 test). However, we did not find any statis-
tically significant difference in OS or PFS in patients with
Objective partial responses to cetuximab-based treatment in patients with KRAS- mutated tumors Figure 3
Objective partial responses to cetuximab-based treatment in patients with KRAS- mutated tumors. (A) Pre- and 
post-cetuximab CT scan showing partial tumor response allowing surgical resection to be performed in patient 6. (B) Pre- and 
post-cetuximab CT scan demonstrating a major tumor response to cetuximab-based treatment in patient 7.
A
Pre-treatment CT scan Post-treatment CT scan
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KRAS-mutated and wild-type tumors. Although this lack
of difference may be reasonably attributed to the limited
sample size, data presented in our study also demon-
strated that authentic and clinically relevant tumor
responses and/or long-term stabilization may be achieved
with cetuximab-based treatment in patients with KRAS-
mutated tumors. Accordingly, we believe that it could be
premature to absolutely exclude cetuximab use in these
patients.
A variant of EGFR extracellular region
Activating mutations of the intracellular kinase domain of
EGFR have been associated with human malignancies and
responsiveness to small molecule EGFR tyrosine kinase
inhibitors[5,10,12]. These mutations are rare or absent in
mCRC, and are thus unlikely to explain the reported anti-
tumor activity of cetuximab in this population. Neverthe-
less, little is known about the extracellular region of EGFR
which represents the binding site of cetuximab. We
sequenced this entire domain and did not find any muta-
tions. However, we observed in 12 patients (37%) a G→A
substitution in exon 13, which encodes a part of the extra-
cellular region of the receptor. The resulting amino acid
substitution Arg to Lys is located at the boundary between
EGFR domain III, which represents the direct interaction
site with cetuximab, and domain IV [24]. In our study,
this variation was observed in 11 patients achieving at
least a stable disease as their best response, but only in 1
patient with progressive disease at its first evaluation.
Moreover, PFS and OS after cetuximab treatment were sig-
nificantly better in the subset of patients displaying this
variant.
This substitution, considered as a polymorphism
(rs11543848 in SNPdb, heterozygosity of 0.41), may be
relatively conservative, as both Arg and Lys are positively
charged amino acids with similar side chains. It is also
found in DNA from normal human lymphocytes [25]
obtained from individuals without malignant diseases
with a frequency of about 20% (homozygous variant) to
50% (heterozygous variant) in the general population
[26].
Furthermore,  EGFR  exon 13 R521K variant has been
already described in other EGFR expressing tumors, such
as gliomas and lung cancer [27]. This EGFR  polymor-
phism, previously described as codon 497 (R497K)
according to an older nomenclature, has been negatively
associated with pelvic recurrence in patients with rectal
cancer treated with chemoradiation [28]. Recent data have
shown that it correlates with a decrease in EGFR phospho-
rylation, decreased invasion, lower nodal involvement,
reduced subsequent metastasis, and longer disease-free
and overall survival in stage II/III colorectal carcinoma
patients who have received curative surgery[26]. In addi-
tion, R521K was associated with oxaliplatin/FU efficacy in
metastatic patients. Interestingly, the resulting amino acid
substitution (Arg to Lys) was shown to significantly
reduce TGFα binding and ligand-induced EGFR signaling
[29]. Thus, it is tempting to speculate that EGFR variant
may alter binding of its specific ligands leading to a partic-
ular phenotype of EGFR signaling. This is particularly
interesting in light of very recent evidences generated from
a microarray study showing that expression of EGFR lig-
ands epiregulin and amphiregulin may predict cetuximab
benefit [15]. An attenuated EGFR-mediated signaling, as
putatively supposed with R521K polymorphism, could be
even more sensitive to targeted receptor inhibition. Alter-
natively, R521K variant could also affect drug binding
and/or effects. However, such preliminary hypotheses
remain to be proven: we have initiated specific functional
studies evaluating the correlation between cetuximab sen-
sitivity and the EGFR exon 13 genotype in various CRC
cell lines and in cellular models expressing wild type
EGFR or the EGFR R521K variant. Importantly, EGFR gen-
otyping on a larger cohort of cetuximab-treated patients,
the accrual of which is currently ongoing, will be essential
to confirm our findings.
Conclusion
In conclusion, genetic factors affecting cetuximab
response are likely to be multiple. EGFR copy number as
well as variations in amino acid composition of the extra-
cellular region may favorably impact cetuximab activity,
whereas KRAS mutations negatively alter the probability
of response, without totally abolishing it. However, these
data from a small-sized patient population are still pre-
liminary. Thus, validation of these results on larger
cohorts and prospective studies are imperatively needed.
Abbreviations
ECD: extracellular domain; EGFR: epidermal growth fac-
tor receptor; FISH: fluorescence in situ hybridization;
mCRC: metastatic colorectal cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AG conceived of the study and its design and was in
charge of its coordination. He participated in data analysis
and performed data interpretation. He drafted the manu-
script. SE carried out the FISH assay and helped to draft
the manuscript. AL carried out the genetic analysis and
participated in data analysis and interpretation. BT–S par-
ticipated in the data analysis and interpretation and
helped to draft the manuscript. MA participated in the
data analysis. GM participated in the data analysis and
interpretation. FB participated in the data interpretation
and helped to draft the manuscript. BE performed the sta-BMC Cancer 2008, 8:169 http://www.biomedcentral.com/1471-2407/8/169
Page 10 of 11
(page number not for citation purposes)
tistical analysis. J–RD, OT and BL participated in patient
treatment and data acquisition. PV helped to conceive and
coordinate the study. J–PB helped to draft the manuscript.
DB participated in designing, coordinating the study, and
in data interpretation. He helped to draft the manuscript.
SO carried out the genetic analysis, participated in data
interpretation and helped to draft the manuscript. FV was
in charge of patient treatment, participated in study
design, coordination, and data interpretation and helped
to draft manuscript. All authors read and approved the
final manuscript.
Acknowledgements
We thank Christian Chabannon, M.D. Ph.D., head of the Biological 
Resource Centre of the Institut PAOLI CALMETTESwhere tumor tissues 
were frozen and stored. We are grateful to F. Birg and C. Mawas for helpful 
discussions. Written consent was obtained from the patient or their rela-
tive for publication of the study.
This work has been supported by Inserm, Institut Paoli-Calmettes, and 
grants from Ligue Nationale Contre le Cancer (Label), Institut National du 
Cancer (Cancéropôle PACA), and the French health ministry (PHRC 
2007).
References
1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling net-
work.  Nat Rev Mol Cell Biol 2001, 2(2):127-137.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A,
Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer.  N Engl J
Med 2004, 351(4):337-345.
3. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B,
Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado
RG: Open-label phase III trial of panitumumab plus best sup-
portive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorec-
tal cancer.  J Clin Oncol 2007, 25(13):1658-1664.
4. Saltz LB, Meropol NJ, Loehrer PJ Sr., Needle MN, Kopit J, Mayer RJ:
Phase II Trial of Cetuximab in Patients With Refractory
Colorectal Cancer That Expresses the Epidermal Growth
Factor Receptor.  J Clin Oncol 2004, 22(7):1201-1208.
5. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P,
Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro
DJ, Rowinsky EK: Multicenter Phase II and Translational Study
of Cetuximab in Metastatic Colorectal Carcinoma Refrac-
tory to Irinotecan, Oxaliplatin, and Fluoropyrimidines.  J Clin
Oncol 2006, 24(30):4914-4921.
6. Schrag D: The price tag on progress--chemotherapy for color-
ectal cancer.  N Engl J Med 2004, 351(4):317-319.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA,
Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis
DN, Christiani DC, Settleman J, Haber DA: Activating mutations
in the epidermal growth factor receptor underlying respon-
siveness of non-small-cell lung cancer to gefitinib.  N Engl J Med
2004, 350(21):2129-2139.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P,
Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ,
Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung
cancer: correlation with clinical response to gefitinib ther-
apy.  Science 2004, 304(5676):1497-1500.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B,
Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M,
Varmus H: EGF receptor gene mutations are common in lung
cancers from "never smokers" and are associated with sen-
sitivity of tumors to gefitinib and erlotinib.  Proc Natl Acad Sci U
S A 2004.
10. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE: Somatic
mutations of EGFR in colorectal cancers and glioblastomas.
N Engl J Med 2004, 351(27):2883.
11. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton
A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP,
Saltz LB: Cetuximab Shows Activity in Colorectal Cancer
Patients With Tumors That Do Not Express the Epidermal
Growth Factor Receptor by Immunohistochemistry.  J Clin
Oncol 2005, 23(9):1803-1810.
12. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A,
Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy
number for epidermal growth factor receptor (EGFR) and
clinical response to antiEGFR treatment in colorectal can-
cer: a cohort study.  Lancet Oncol 2005, 6(5):279-286.
13. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF,
Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Lau-
rent-Puig P: KRAS mutation status is predictive of response to
cetuximab therapy in colorectal cancer.  Cancer Res 2006,
66(8):3992-3995.
14. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais
MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B,
Sabourin JC, Michot F, Michel P, Frebourg T: Clinical relevance of
KRAS mutation detection in metastatic colorectal cancer
treated by Cetuximab plus chemotherapy.  Br J Cancer 2007,
96(8):1166-1169.
15. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT,
Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR,
Krishnamurthi SS, Burris HA III, Poplin EA, Hidalgo M, Baselga J, Clark
EA, Mauro DJ: Expression of Epiregulin and Amphiregulin and
K-ras Mutation Status Predict Disease Control in Metastatic
Colorectal Cancer Patients Treated With Cetuximab.  J Clin
Oncol 2007, 25(22):3230-3237.
16. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni
M, Veronese S, Siena S, Bardelli A: Oncogenic activation of the
RAS/RAF signaling pathway impairs the response of meta-
static colorectal cancers to anti-epidermal growth factor
receptor antibody therapies.  Cancer Res 2007, 67(6):2643-2648.
17. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M,
Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L: PTEN loss of
expression predicts cetuximab efficacy in metastatic color-
ectal cancer patients.  Br J Cancer 2007, 97(8):1139-1145.
18. WHO handbook for reporting of cancer treatment.  In Pathol-
ogie Biologie Volume 48. Geneva (Switzerland) , World Health Organ-
isation Offset Publication; 1979. 
19. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N,
Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R,
Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR: Increased
epidermal growth factor receptor gene copy number is asso-
ciated with poor prognosis in head and neck squamous cell
carcinomas.  J Clin Oncol 2006, 24(25):4170-4176.
20. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E,
Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E,
Nichelatti M, Gambacorta M, Siena S: Epidermal Growth Factor
Receptor Gene Copy Number and Clinical Outcome of Met-
astatic Colorectal Cancer Treated With Panitumumab.  J Clin
Oncol 2007, 25(22):3238-3245.
21. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M,
Chung KY, Yao D, Paty PB, Gerald W, Chen B: Epidermal growth
factor receptor expression and gene amplification in color-
ectal carcinoma: an immunohistochemical and chromogenic
in situ hybridization study.  Mod Pathol 2005, 18(10):1350-1356.
22. Sauer T, Guren MG, Noren T, Dueland S: Demonstration of
EGFR gene copy loss in colorectal carcinomas by fluores-
cence in situ hybridization (FISH): a surrogate marker for
sensitivity to specific anti-EGFR therapy?  Histopathology 2005,
47(6):560-564.
23. Al-Kuraya K, Novotny H, Bavi PP, Siraj AK, Uddin S, Ezzat A, Al Sanea
N, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R,
Sauter G, Terracciano L, Tornillo L: HER2, TOP2A, CCND1,
EGFR, And C-MYC oncogene amplification in colorectal
cancer.  J Clin Pathol 2006:jcp.2006.038281.
24. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM:
Structural basis for inhibition of the epidermal growth factor
receptor by cetuximab.  Cancer Cell 2005, 7(4):301-311.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:169 http://www.biomedcentral.com/1471-2407/8/169
Page 11 of 11
(page number not for citation purposes)
25. Moriai T, Kobrin MS, Korc M: Cloning of a variant epidermal
growth factor receptor.  Biochem Biophys Res Commun 1993,
191(3):1034-1039.
26. Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Wang HS, Su
Y: Epidermal growth factor receptor R497K polymorphism is
a favorable prognostic factor for patients with colorectal car-
cinoma.  Clin Cancer Res 2007, 13(12):3597-3604.
27. Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN,
Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell
JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M,
Holland EC: Molecular study of malignant gliomas treated
with epidermal growth factor receptor inhibitors: tissue
analysis from North American Brain Tumor Consortium
Trials 01-03 and 00-01.  Clin Cancer Res 2005, 11(21):7841-7850.
28. Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-
Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ:
Gene polymorphisms of epidermal growth factor receptor
and its downstream effector, interleukin-8, predict oxalipla-
tin efficacy in patients with advanced colorectal cancer.  Clin
Colorectal Cancer 2005, 5(2):124-131.
29. Moriai T, Kobrin MS, Hope C, Speck L, Korc M: A Variant Epider-
mal Growth Factor Receptor Exhibits Altered Type {alpha}
Transforming Growth Factor Binding and Transmembrane
Signaling.  PNAS 1994, 91(21):10217-10221.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/169/pre
pub